A Phase I single-dose study to evaluate the pharmacokinetics of CORT113176 softgel capsules in healthy subjects
An open-label, drug-drug interaction study designed to evaluate the potential effect of miricorilant on cytochrome P450 2C8, 2C9, 3A4, uridine-diphospho-glucuronosyltransferase 1A1 enzyme activity, and breast cancer resistance protein activity using probe substrates in healthy male and female subjects
A Phase I pharmacokinetic assessment of zavacorilant softgel capsule formulation, including dose proportionality and food effect in healthy subjects
100 Clinical Results associated with Corcept Therapeutics (United States)
0 Patents (Medical) associated with Corcept Therapeutics (United States)
100 Deals associated with Corcept Therapeutics (United States)
100 Translational Medicine associated with Corcept Therapeutics (United States)